What Happens If You Inject Wegovy Into a Stretch Mark?

Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide injections require subcutaneous placement into healthy adipose tissue, typically the abdomen, thigh, or upper arm. Stretch marks represent altered skin architecture where collagen has broken down, and injecting into these areas can compromise medication absorption and increase local irritation. PlexusDx patients receive detailed injection guidance to ensure optimal results.

Why Stretch Marks Are Not Safe Injection Sites

Stretch marks form when rapid skin expansion or weight loss damages the dermis—the collagen-rich layer beneath the epidermis. This scarring creates thin, inelastic tissue that differs structurally from surrounding skin. When you attempt to inject medication into a stretch mark, the compromised tissue cannot reliably absorb the compound into the subcutaneous fat layer where it should distribute. Instead, the medication may pool superficially, disperse unpredictably, or cause localized inflammation and discomfort.

The subcutaneous tissue beneath stretch marks often contains less viable fat than unmarked skin, reducing the depot effect that semaglutide relies on for steady systemic absorption. Clinical practice guidelines for subcutaneous GLP-1 therapy recommend injecting into intact, healthy adipose tissue to maintain consistent pharmacokinetics. Deviating from these sites introduces variability in drug delivery and may compromise your treatment outcomes.

Recommended Injection Sites for Semaglutide Therapy

The FDA-cleared injection sites for semaglutide include the abdomen, upper thigh, and upper arm. Patients should rotate between these three regions to prevent lipodystrophy—localized fat atrophy or hypertrophy that can occur with repeated injections at identical sites. Within the abdomen, avoid the 2-inch area around the navel. Rotation schedules prevent tissue damage and ensure consistent medication absorption across different injection cycles.

PlexusDx recommends mapping out injection sites in advance, spacing needles at least one finger-width apart and alternating between left and right sides of the body. Avoid any area with active inflammation, bruising, infection, or compromised skin integrity—including stretch marks, tattoos, or previous injection sites still healing. This systematic approach optimizes therapeutic response and patient safety over months of treatment.

How Injection Site Selection Affects Treatment Efficacy

Subcutaneous injection success depends on needle placement in the fat layer between skin and muscle. The subcutaneous route allows semaglutide to enter the bloodstream gradually over several days, creating the sustained GLP-1 receptor activation that suppresses appetite and slows gastric emptying. If medication deposits into scarred or thin tissue instead of viable fat, absorption becomes erratic. Some patients report reduced appetite suppression or inconsistent side effects when they inadvertently inject near problematic sites.

Research on subcutaneous peptide delivery shows that tissue quality directly correlates with bioavailability—the percentage of injected drug that reaches systemic circulation. Lean or atrophied tissue beneath stretch marks has fewer blood vessels and less interstitial fluid, slowing absorption and potentially increasing local adverse reactions. Consistent, effective weight loss with semaglutide requires delivering each dose into healthy, well-perfused adipose tissue.

Genetic Factors in GLP-1 Response and Injection Considerations

Individual variation in GLP-1 receptor sensitivity means that some patients respond more dramatically to semaglutide than others—a difference partly explained by genetic variation at the GLP1R locus. The PlexusDx Precision Peptide Genetic Test analyzes variants including GLP1R rs6923761, which influences receptor function and may predict medication response intensity. Patients with genetic predispositions toward robust GLP-1 signaling may experience nausea or rapid appetite suppression, making injection site consistency even more critical to avoid dose-delivery surprises.

Beyond GLP1R, variants in FTO rs9939609 and MC4R rs17782313 affect appetite signaling and weight regulation. When pharmacogenetic insights show heightened sensitivity to GLP-1 effects, maintaining standardized injection technique—into healthy tissue sites only—helps prevent unpredictable symptoms. PlexusDx members can access the Precision Peptide Genetic Test as a $99 add-on after their first month of treatment, enabling personalized injection and dosing strategies.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What happens if I accidentally inject semaglutide into a stretch mark?

Accidental injection into scarred tissue may cause localized pain, bruising, or reduced medication absorption that week. Stop injecting into that area immediately and resume rotation at healthy sites. Contact your PlexusDx provider if you experience unusual symptoms or if you notice multiple injections in compromised areas. One accidental injection rarely causes serious harm, but systematic avoidance of stretch marks protects your ongoing treatment.

Can stretch marks develop from semaglutide injections?

Semaglutide itself does not cause stretch marks. However, rapid weight loss—which semaglutide facilitates—can paradoxically contribute to new stretch marks if skin loses elasticity faster than it can remodel. Existing stretch marks will not worsen from proper subcutaneous injection, but loose skin following significant weight loss may benefit from dermatologic assessment. This is a separate cosmetic concern unrelated to injection site selection.

How does PlexusDx semaglutide pricing work if I need injection site rotation?

PlexusDx compounded semaglutide injections start at $149 per month, with your dose adjusting as needed without price increases—your dose may go up, but your price won't. This flat-rate model means you can commit to proper injection rotation without worrying that rotating sites will trigger additional charges. All PlexusDx medications are compounded at licensed 503A pharmacies and ship to all 50 states.

Are there signs that my injection sites are becoming damaged?

Watch for persistent lumps, hardened areas, dimpling, or localized fat loss at injection sites—collectively called lipodystrophy. If you notice these changes, pause injections in that region for several weeks and rotate exclusively to fresh sites. Severe or spreading lipodystrophy warrants discussion with your provider. Proper site rotation and avoidance of stretch marks significantly reduce lipodystrophy risk.

Does the Precision Peptide Genetic Test help with injection planning?

While the PlexusDx Precision Peptide Genetic Test ($99 add-on) primarily reveals your genetic predispositions to GLP-1 efficacy and appetite regulation—mapping 14 pathways and 49 peptides—it informs your overall treatment strategy. Patients with genetic variants showing heightened GLP-1 sensitivity benefit from ultra-consistent injection technique and site selection. Genetic insights + proper injection hygiene = optimized outcomes.

Related Reading

• What Determines If You Are A Morning Person Or A Night Owl
• Can You Avoid Diabetes If It Runs In Your Family
• Ro Wegovy
• Mochi Wegovy

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.